TY - JOUR
T1 - Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines
AU - van Dalen, Elvira C.
AU - van der Pal, Helena J.H.
AU - van den Bos, Cor
AU - Kok, Wouter E.M.
AU - Caron, Huib N.
AU - Kremer, Leontien C.M.
N1 - Funding Information:
The authors thank J.B. Reitsma and J.H. van der Lee for their statistical advice, R.C. Heinen for helping in identifying all eligible patients and M.M. Geenen for her input in the study design and the provision of pregnancy data. This study was supported by the Foundation of Paediatric Cancer Research (SKK), Amsterdam, The Netherlands.
PY - 2006/10
Y1 - 2006/10
N2 - The cumulative incidence of peripartum anthracycline-induced clinical heart failure (A-CHF) was evaluated in a cohort of 53 childhood cancer survivors who had delivered one or more children. None of them developed peripartum A-CHF (cumulative incidence 0%; 95% confidence interval (CI) 0-5.7%). The mean follow-up time after the first administration of anthracycline therapy was 20.3 years. They received a mean cumulative anthracycline dose of 267 mg/m2. It is worth noticing that even 2 patients with A-CHF before pregnancy did not develop peripartum A-CHF. Since there were no cases of peripartum A-CHF in our cohort, it was not possible to evaluate associated risk factors. In conclusion, this study demonstrates a low risk of developing peripartum A-CHF in childhood cancer survivors. However, more cohort studies with adequate power and long-term follow-up are needed to reliably evaluate the cumulative incidence of peripartum anthracycline-induced cardiotoxicity (both clinical and asymptomatic) and associated risk factors.
AB - The cumulative incidence of peripartum anthracycline-induced clinical heart failure (A-CHF) was evaluated in a cohort of 53 childhood cancer survivors who had delivered one or more children. None of them developed peripartum A-CHF (cumulative incidence 0%; 95% confidence interval (CI) 0-5.7%). The mean follow-up time after the first administration of anthracycline therapy was 20.3 years. They received a mean cumulative anthracycline dose of 267 mg/m2. It is worth noticing that even 2 patients with A-CHF before pregnancy did not develop peripartum A-CHF. Since there were no cases of peripartum A-CHF in our cohort, it was not possible to evaluate associated risk factors. In conclusion, this study demonstrates a low risk of developing peripartum A-CHF in childhood cancer survivors. However, more cohort studies with adequate power and long-term follow-up are needed to reliably evaluate the cumulative incidence of peripartum anthracycline-induced cardiotoxicity (both clinical and asymptomatic) and associated risk factors.
KW - Anthracyclines
KW - Childbirth
KW - Childhood cancer survivors
KW - Congestive heart failure
KW - Pregnancy
UR - http://www.scopus.com/inward/record.url?scp=33749133823&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2006.04.014
DO - 10.1016/j.ejca.2006.04.014
M3 - Article
C2 - 16919450
AN - SCOPUS:33749133823
SN - 0959-8049
VL - 42
SP - 2549
EP - 2553
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 15
ER -